Skip to content
AV Peptide

EDITORIAL DESK / CORRECTIONS

Send the Claim and the Source

The most useful correspondence identifies the exact page, sentence, and supporting record.

Editorial correspondence

AV Peptide welcomes corrections to the research record: a mislabeled study design, an endpoint described too broadly, a population boundary that needs sharpening, or a listed source that no longer resolves. A useful note identifies the page, quotes the exact passage, and supplies the publication or official record that supports a correction. That structure allows the editorial desk to test the claim rather than trade impressions.

Editorial mailbox: editors@avpeptide.com

The mailbox is intended for source and accuracy work across MOTS-c, CJC-1295, tesamorelin, ipamorelin, and the GH/IGF-1 evidence framework. Publication authors, researchers, clinicians, and careful readers are all welcome to flag an issue. Replies are not guaranteed, but specific corrections receive priority over general promotion.

Outside the desk's scope

The editorial desk does not provide personal medical guidance, assess whether a compound fits an individual, interpret laboratory results for a patient, or recommend a dose, schedule, route, or combination. It does not sell peptides, identify vendors, evaluate research-market batches, arrange prescriptions, or provide anti-doping clearance. Supplier pitches, affiliate proposals, and requests to remove evidence limits from copy are not editorial corrections.

Clinical decisions require a licensed professional who can evaluate medical history, current treatment, regulated options, and jurisdiction-specific rules. Questions about tested sport require the relevant anti-doping authority. AV Peptide can explain what a study measured and where its inference stops; it cannot turn that literature summary into an individualized decision.

For a source already used on the site, the references page is the fastest audit route. For a cross-compound question, the comparison matrix separates mechanism, biomarker, tissue outcome, and clinical outcome before any conclusion is drawn.